Valore202020212022202320242025TTMSpese di vendita, generali e amministrative188.27 M567 M1.13 B1.75 B1.32 B1.15 B1.02 BRicerca e sviluppo1.37 B1.99 B3.29 B4.84 B4.54 B3.13 B3.13 BReddito operativo-763.14 M13.3 B9.42 B-4.24 B-3.94 B-3.07 B-3.07 BProventi non operativi, Totale-53.84 M-65 M124 M323 M381 M365 M365 MOneri finanziari, al netto degli interessi capitalizzati9.89 M17 M29 M38 M24 M3 M—Proventi non operativi, esclusi gli oneri finanziari-57.65 M-53 M140 M409 M444 M370 M373 MEntrate/uscite straordinarie-6.08 M-29 M-45 M-124 M-87 M-8 M-8 MUtile al lordo delle imposte-744.51 M13.29 B9.57 B-3.94 B-3.61 B-2.77 B-2.77 BQuota di utile———-35 M-52 M-8 M-8 MImposte2.55 M1.08 B1.21 B772 M-46 M54 M54 MInteressi di minoranza———————Altri proventi/oneri al netto delle imposte——-28 M-7 M-60 M-77 M-77 MUtile netto al lordo delle attività cessate-747.06 M12.2 B8.36 B-4.71 B-3.56 B-2.82 B-2.82 BAttività cessate———————Utile netto-747.06 M12.2 B8.36 B-4.71 B-3.56 B-2.82 B-2.82 BRegolazione della diluizione0——————Dividendi privilegiati0——————Utile netto diluito attribuibile agli azionisti ordinari-747.06 M12.2 B8.36 B-4.71 B-3.56 B-2.82 B-2.82 BUtile base per azione (EPS base)—30.3121.26-12.33-9.28-7.26-7.26Utile diluito per azione (EPS diluito)—28.2920.12-12.33-9.28-7.26-7.26Numero medio di azioni ordinarie in circolazione—403 M394 M382 M384 M389 M1.55 BAzioni diluite in circolazione—431 M416 M382 M384 M389 M1.55 BEBITDA-731.89 M13.53 B9.77 B-3.62 B-3.76 B-2.86 B-2.86 BEBIT-763.14 M13.3 B9.42 B-4.24 B-3.94 B-3.07 B-3.07 BCosto del fatturato7.93 M2.62 B5.42 B4.69 B1.46 B868 M868 MAltri costi del venduto——1.92 B2.34 B555 M315 M315 MAmmortamento e svalutazione (liquidità)31.25 M232 M348 M617 M185 M211 M211 M
Moderna Inc
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a respiratory syncytial virus vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.